ALGSAligos Therapeutics, Inc.
- GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through ...
- GlobeNewswire
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies ...
- GlobeNewswire
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies ...
- GlobeNewswire
Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026 ...
- GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through ...
- GlobeNewswire
Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for ...
- GlobeNewswire
Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
SOUTH SAN FRANCISCO, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address ...
- GlobeNewswire
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical ...
- Analyst Upgrades
Lake Street Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $45
Lake Street analyst Daniel Brims initiates coverage on Aligos Therapeutics with a Buy rating and announces Price Target of $45. ...
- GlobeNewswire
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented40% ...
- Analyst Upgrades
Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics with a Overweight rating and announces Price Target of $20. ...
- GlobeNewswire
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies ...
- GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class ...
- GlobeNewswire
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for ...
- GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through ...
- GlobeNewswire
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program in Greater ChinaAmoytop ...
- GlobeNewswire
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size increased to optimize powering; futility criteria not metStudy drugs were ...
- Analyst Upgrades
WestPark Capital Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $48
WestPark Capital initiates coverage on Aligos Therapeutics with a Buy rating and announces Price Target of $48. ...
- Analyst Upgrades
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48
Jefferies analyst Anthea Li assumes Aligos Therapeutics with a Buy rating and lowers Price Target of $48. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics with a Buy and maintains $50 price target. ...
- GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class ...
- GlobeNewswire
Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for ...
- GlobeNewswire
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies ...
- GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company")), a clinical stage biopharmaceutical company focused on improving patient outcomes through ...
- GlobeNewswire
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies ...